2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

2:30PM-4:00PM: Abstract Number: 886

CC-220 Decreases B-Cell Subsets and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus (SLE) Patients and Is Associated with Skin Improvement: Pharmacodynamic Results from a Phase IIa Proof of Concept Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 861

CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice

Rheumatoid Arthritis – Animal Models

2:30PM-4:00PM: Abstract Number: 884

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

2:30PM-4:00PM: Abstract Number: 833

Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin

B Cell Biology and Targets in Autoimmune Disease

2:30PM-4:00PM: Abstract Number: 834

Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis

B Cell Biology and Targets in Autoimmune Disease

2:30PM-4:00PM: Abstract Number: 871

Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus in Patients without Obstructive Coronary Artery Disease

Rheumatoid Arthritis – Clinical Aspects I: Cardiac Comorbidities

2:30PM-4:00PM: Abstract Number: 870

Detection of Left Ventricular Regional Function in Rheumatoid Arthritis Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging

Rheumatoid Arthritis – Clinical Aspects I: Cardiac Comorbidities

2:30PM-4:00PM: Abstract Number: 878

Diagnosis of Salivary Gland Lymphoma in Sjogren’s Syndrome Utilizing Ultrasound-Guided Core Needle Biopsies

Sjögren's Syndrome I: Clinical Assessment and Trial Outcomes

2:30PM-4:00PM: Abstract Number: 874

Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sjögren’s Syndrome: Results of Multicentre Double-Blind Randomised Controlled Trial Sub-Study

Sjögren's Syndrome I: Clinical Assessment and Trial Outcomes

2:30PM-4:00PM: Abstract Number: 860

Effective Treatment of Persistent Arthritis Pain Requires Co-Modulation of TNF and Type I Interferon

Pain – Basic and Clinical Aspects Oral

2:30PM-4:00PM: Abstract Number: 845

Effectiveness of Brief Group Psychoanalytic Psychotherapy in Patients with Systemic Lupus Erythematosus and Follow-up

ARHP Psychosocial Impact on Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 893

Efficacy and Safety of Belimumab in Combination with Azathioprine for Remission Maintenance in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: A Multicenter Randomized, Placebo-Controlled Study

Vasculitis I: Clinical Trials and Outcomes

2:30PM-4:00PM: Abstract Number: 876

Epidemiologic Subsets Drive a Differentiated Clinical and Immunological Presentation of Primary Sjögren Syndrome: Analysis of 9302 Patients from the Big Data International Sjögren Cohort

Sjögren's Syndrome I: Clinical Assessment and Trial Outcomes

2:30PM-4:00PM: Abstract Number: 863

Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology

Rheumatoid Arthritis – Animal Models

2:30PM-4:00PM: Abstract Number: 835

Generation of an Efficient CRISPR-Cas9 Editing Technique in Human Primary B Cells for the Targeted Study of Autoimmune Susceptibility Genes

B Cell Biology and Targets in Autoimmune Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.